How do you choose between Ipilimumab/Nivolumab (Checkmate 9LA) vs Durvalumab/Tremelimumab (POSEIDON) with chemotherapy in first line for mNSCLC with high PDL1, KEAP, and/or STK11 mutations?
Community PollStarted
What immunotherapy backbone do you use in patients with non-EGFR/ALK/ROS1 metastatic lung adenocarcinoma with baseline KEAP and/or STK11 mutations?
37 physicians have voted
Join Mednetto vote and see how they answered.